Dry Powder Inhaler Market Segmentation, Scope And Forecast 2025 - 2034

Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations

What Is the Expected Market Growth Rate for the Dry Powder Inhaler Market?
The dry powder inhaler market size has grown steadily in recent years. It will grow from $21.25 billion in 2024 to $22.18 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to renewed interest in sustainable building materials, cultural preservation and heritage restoration, rise in green building practices, local sourcing and community involvement, regulatory support and building codes.

The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $26.82 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies, global economic factors. Major trends in the forecast period include increased research and development, renewed interest in traditional building techniques, advancements in material technology, architectural and design trends, regulatory support for sustainable construction.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13430&type=smp

What Are the Primary Growth Contributors in the Dry Powder Inhaler Market?
The growing prevalence of respiratory diseases is expected to propel the growth of the dry powder inhaler market going forward. Respiratory diseases refer to respiratory disorders or lung diseases, encompassing a broad category of medical conditions affecting the respiratory system. Dry powder inhalers are essential in treating respiratory conditions such as asthma, COPD, and cystic fibrosis as they deliver medicine directly to the lungs, where it is most effective. It is a promising alternative to traditional drug delivery methods for respiratory diseases. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (copd) projected that COPD cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Among these the number of female cases is expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Furthermore, the majority of cases are anticipated in low- and middle-income regions, where the prevalence will more than double that of high-income regions by 2050. Therefore, the growing prevalence of respiratory diseases will drive the growth of the dry powder inhaler market.

How Is the Dry Powder Inhaler Market Segmented?
The dry powder inhalermarket covered in this report is segmented –

1) By Product: Single-Dose Inhalers, Multi-Dose Inhalers
2) By Function: Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Other Applications
4) By End User: Hospitals And Clinics, Homecare Settings, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Single-Dose Inhalers: Capsule-Based Inhalers, Diskus-Based Inhalers
2) By Multi-Dose Inhalers: Blister-Based Inhalers, Rotahaler-Based Inhalers

Which Trends Are Most Likely to Influence Dry Powder Inhaler Market Growth in the Next Decade?
Major companies operating in the dry powder inhaler market are developing innovative products with muscarinic antagonist for treating chronic obstructive pulmonary disease (COPD) and expanding their product portfolio. A muscarinic antagonist is a drug that inhibits the muscarinic acetylcholine receptor. It controls and treats various illnesses, such as COPD and organophosphate poisoning. For instance, In March 2024, Berry Global, a US-based company known for developing and manufacturing a wide range of flexible packaging solutions, launched its new dry powder inhaler at Pharma pack. The inhaler is designed to enhance drug delivery for respiratory conditions like COPD and asthma, offering a customizable solution for pharmaceutical companies.

Which Companies Hold the Largest Share in the Dry Powder Inhaler Market?
Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

Get the full dry powder inhaler market report here:
https://www.thebusinessresearchcompany.com/report/dry-powder-inhaler-global-market-report

How Are Market Trends Differentiating Across Key Regions in the Dry Powder Inhaler Market?
North America was the largest region in the dry powder inhaler market in 2024. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company